BioNTech SE

BioNTech’s latest oncology trial results—Pumitamig and Gotistobart—offer new hope amid mRNA regulatory headwinds, showing promise in breast and lung cancer while the stock lingers near a 52‑week low.

BioNTech’s Gotistobart cuts overall mortality by 54% in metastatic lung‑cancer Phase 3 trial, showing a groundbreaking survival benefit and safe profile.

BioNTech SE: Analyse des mRNA‑Wettbewerbs, der potenziellen CureVac‑Übernahme und Kursziel‑Bewertung – Chancen und Risiken für Anleger.

BioNTech’s takeover of CureVac moves forward—over 99% shareholder support, $1.25 bn valuation, and a December 3 deadline. Find out how this merger could reshape Europe’s biotech scene.

BioNTech SE, a leading German biotechnology company, continues to make significant strides in the healthcare sector, driven by its commitment to developing innovative cancer treatments and its robust market presence.

BioNTech SE has reported positive interim data from a Phase-2 study of its bispecific antibody Pumitamig in patients with extensive-stage small cell lung cancer, showing encouraging anti-tumor activity and a solid safety profile.

BioNTech SE has demonstrated resilience and strategic foresight, reporting improved financial performance and making significant strides towards financial stability despite navigating financial challenges and a potential acquisition of CureVac.

BioNTech SE has announced a strategic partnership with Bristol-Myers Squibb to co-develop and co-commercialize its innovative bispecific antibody candidate, BNT327, for cancer treatment.

BioNTech and Bristol Myers Squibb have formed a billion-euro alliance to co-develop and co-commercialize a groundbreaking cancer treatment, BNT327, which has the potential to revolutionize cancer care.

BioNTech SE’s stock price has declined due to disappointing study results from a competitor, casting uncertainty over its new cancer therapy initiatives and sparking a broader debate about its oncology pipeline.